8 sources·Health

Eli Lilly's Zepbound Outperforms Wegovy in Weight Loss Study

Eli Lilly's Zepbound shows greater weight loss than Novo Nordisk's Wegovy, with average reduction of 20.2% versus 13.7%.

25%

63%

13%

The distribution of story sources: left-leaning (blue), center (light gray), and right-leaning (red).

Reliable

The underlying sources consistently report facts with minimal bias, demonstrating high-quality journalism and accuracy.

Balanced

The underlying sources are either a balanced mix of left and right or primarily centrist.

Subscribe to unlock this story

We really don't like cutting you off, but you've reached your monthly limit. At just $3/month or $30/year, subscriptions are how we keep this project going. Start your free 7-day trial today!

Get Started

No highlights available for this story.

Updated: Dec 4th, 2024, 2:53 PM ET

Summary

A summary of the key points of this story verified across multiple sources.

Eli Lilly's latest study revealed Zepbound results in an average weight loss of 20.2% compared to 13.7% for Wegovy, with 47% more weight loss overall. The trial, funded by Lilly and involving 751 participants, confirmed previous findings and may influence the obesity drug market. Zepbound's increased sales and approval as a dual GIP and GLP-1 agonist might enhance its competitive edge, but both drugs are associated with mild gastrointestinal side effects. Further data on health outcomes beyond weight loss is anticipated.

Perspectives

Compare opinions on this story from liberal (Left), conservative (Right) or center-leaning news organizations.

No center-leaning sources available for this story.

History

A summary of how this story has evolved over the last 24 hours.